ScandiDos has recently implemented a new share issue that raised SEK 24 million before issue costs. Lindahl has assisted in the issue.
ScandiDos is a leader in advanced dosimetry and quality assurance of modern radiation therapy of cancer. Headquartered in Uppsala Science Park, where among other things, development is performed. ScandiDos is since April 2014 listed on First North. Erik Penser Aktiebolag acted as financial advisor in the capital raising.
Lindahl's team consisted of Mattias Prage (lead partner), Helena Lindbäck, Sofia Lysén and Marcus Andersson.
